Gilenya (fingolimod)

A Pediatric MS Medication Gets the OK

Until about a week ago, no medication was approved in the U.S. to treat patients with pediatric-onset MS (POMS). Now there is one. The Food and Drug Administration (FDA) has given its OK to use Gilenya (fingolimod) to treat relapsing MS in children and adolescents starting at…

Gilenya Seen as Most Effective in Younger and Previously Untreated Patients with Relapsing MS

A study analyzing results from three Phase 3 clinical trials shows that Gilenya (fingolimod) effectively prevents relapses in different types of relapsing multiple sclerosis (MS) patients, with the therapy being most efficient in younger patients and those without previous treatment. The findings highlight the importance of starting treatment early, and not…